-
RNA Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Avidity Biosciences (RNA)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 222.66 mm | 222.66 mm | 222.66 mm | 222.66 mm | 222.66 mm | 222.66 mm |
Cash burn (monthly) | 50.11 mm | (no burn) | 40.33 mm | 31.58 mm | 33.29 mm | 25.07 mm |
Cash used (since last report) | 127.10 mm | n/a | 102.30 mm | 80.10 mm | 84.44 mm | 63.60 mm |
Cash remaining | 95.56 mm | n/a | 120.36 mm | 142.56 mm | 138.22 mm | 159.06 mm |
Runway (months of cash) | 1.9 | n/a | 3.0 | 4.5 | 4.2 | 6.3 |
13F holders | Current |
---|---|
Total holders | 237 |
Opened positions | 51 |
Closed positions | 59 |
Increased positions | 86 |
Reduced positions | 74 |
13F shares | Current |
---|---|
Total value | 3.36 tn |
Total shares | 134.90 mm |
Total puts | 717.10 k |
Total calls | 517.20 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 16.51 mm | $480.10 bn |
T. Rowe Price | 11.04 mm | $321.13 mm |
BlackRock | 9.93 mm | $288.83 bn |
Vanguard | 9.43 mm | $274.28 bn |
Wellington Management | 8.11 mm | $235.73 bn |
RTW Investments | 7.93 mm | $230.69 bn |
Avoro Capital Advisors | 7.50 mm | $218.10 bn |
JHG Janus Henderson | 7.05 mm | $205.13 bn |
Ra Capital Management | 6.30 mm | $183.22 bn |
BMY Bristol-Myers Squibb | 5.08 mm | $219.36 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 25 | W. Michael Flanagan | Common Stock | Sell | Dispose S | No | Yes | 30.1307 | 20,000 | 602.61 k | 91,975 |
11 Mar 25 | W. Michael Flanagan | Common Stock | Option exercise | Acquire M | No | Yes | 14.22 | 20,000 | 284.40 k | 111,975 |
11 Mar 25 | W. Michael Flanagan | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 14.22 | 20,000 | 284.40 k | 116,500 |
3 Mar 25 | Kathleen P. Gallagher | Common Stock | Sell | Dispose S | No | Yes | 29.414 | 5,875 | 172.81 k | 50,554 |
3 Mar 25 | Kathleen P. Gallagher | Common Stock | Option exercise | Acquire M | No | Yes | 14.7 | 5,875 | 86.36 k | 56,429 |
3 Mar 25 | Kathleen P. Gallagher | Stock Option Common Stock | Option exercise | Dispose M | No | No | 14.7 | 5,875 | 86.36 k | 19,375 |
3 Feb 25 | Kathleen P. Gallagher | Common Stock | Sell | Dispose S | No | Yes | 32.1563 | 5,875 | 188.92 k | 50,554 |
3 Feb 25 | Kathleen P. Gallagher | Common Stock | Option exercise | Acquire M | No | Yes | 16.65 | 5,875 | 97.82 k | 56,429 |
3 Feb 25 | Kathleen P. Gallagher | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 16.65 | 5,875 | 97.82 k | 34,675 |
22 Jan 25 | Kathleen P. Gallagher | Common Stock | Sell | Dispose S | No | Yes | 30.1609 | 5,629 | 169.78 k | 50,554 |